Drugging histone methyltransferases in cancer

Area of Science:

• Oncology
• Epigenetics
• Pharmacology

Background:

• Targeting chromatin-modifying enzymes represents a significant strategy in cancer treatment.
• Histone methyltransferases, especially EZH2, are key epigenetic regulators implicated in cancer development.
• Inhibitors of these enzymes are under investigation in early-phase clinical trials.

Purpose of the Study:

• To review recent advancements in histone methyltransferase inhibitors for cancer therapy.
• To discuss the clinical progress and challenges associated with these targeted agents.
• To provide an overview of EZH2 inhibitors and their therapeutic potential.

Main Methods:

• Literature review of preclinical and clinical studies on histone methyltransferase inhibitors.
• Analysis of data from ongoing phase I/II clinical trials.
• Synthesis of current research on EZH2 and related epigenetic targets.

Main Results:

• Positive preliminary results observed in hematological malignancies and specific solid tumors.
• Demonstrated antitumor activity of EZH2 inhibitors in certain cancer types.
• Identification of specific tumor mutational backgrounds benefiting from this therapy.

Conclusions:

• Histone methyltransferase inhibitors, particularly EZH2-targeting compounds, are a promising class of anticancer drugs.
• Clinical efficacy is emerging, but challenges in patient selection and resistance mechanisms need to be overcome.
• Further research and clinical development are crucial for successful implementation in cancer treatment.